Litcius/Paper detail

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer

Ursula A. Matulonis, Ignace Vergote, Kathleen N. Moore, Lainie P. Martin, Cesar M. Castro, Lucy Gilbert, Xia Yu, Michael Method, James Stec, Michael J. Birrer, David M. O’Malley

2025Gynecologic Oncology11 citationsDOI

Topics & Concepts

MedicinePembrolizumabOvarian cancerConjugateFolate receptorAntibodyDrugAntibody-drug conjugateOncologyInternal medicineMonoclonal antibodyCancer researchCancerPharmacologyImmunologyImmunotherapyCancer cellMathematical analysisMathematicsOvarian cancer diagnosis and treatmentHER2/EGFR in Cancer ResearchAdvanced Breast Cancer Therapies
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer | Litcius